Loading...

CERE

Cerevel Therapeutics Holdings Inc · NASDAQ

Performance

+0.14%

1W

-0.95%

1M

-1.54%

3M

+0.8%

6M

-1.77%

YTD

+25.94%

1Y

Profile

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Investment Analysis Report: CERE

Overview

CERE is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has shown significant growth in market capitalization over the years, indicating potential investor interest. In this report, we will analyze CERE's financial health, earnings and...

See more ...

Technical Analysis of CERE 2024-05-31

Overview:

In analyzing the technical indicators for CERE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...

See more ...

Recent News & Updates